trastuzumab (Herceptin)

1.	Esteva, Francisco J: 14 articles (04/2008 - 04/2002)
2.	Zielinski, Christoph C: 13 articles (12/2007 - 03/2004)
3.	Altundag, Kadri: 11 articles (01/2008 - 01/2004)
4.	Slamon, Dennis J: 10 articles (05/2007 - 02/2002)
5.	Montemurro, Filippo: 9 articles (05/2006 - 02/2003)
6.	Aglietta, Massimo: 8 articles (05/2006 - 02/2003)
7.	Isola, Jorma: 8 articles (02/2008 - 12/2004)
8.	Cognetti, Francesco: 8 articles (05/2008 - 11/2004)
9.	Bartsch, Rupert: 7 articles (12/2007 - 07/2004)
10.	Pegram, Mark D: 7 articles (04/2006 - 01/2003)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 06/01/2002 - "Hopefully, information from these trials will help resolve questions regarding the efficacy of various combinations and dosing schedules so that trastuzumab may be used most effectively in the treatment of HER2-overexpressing breast cancer in both the metastatic and the adjuvant settings." 03/01/2002 - "In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab." 09/01/2007 - "In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable." 07/01/2004 - "CONCLUSION: These studies suggest that (225)Ac-labeled trastuzumab may be a potent therapeutic agent against metastatic breast cancer cells exhibiting intermediate to high HER2/neu expression." 12/01/2003 - "With trastuzumab achieving excellent results in the treatment of HER-2/neu-positive advanced disease and under extensive evaluation in major clinical trials for its potential efficacy when used at earlier clinical stages, the potential role(s) for HER-2/neu testing as a predictor of response to other therapies being resolved by large prospective clinical outcome studies, and the more convenient gene-based chromogenic in situ hybridization technique "waiting in the wings," the saga of HER-2/neu testing in breast cancer will continue to unfold over the next several years." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 03/01/2006 - "In patients with HER2-positive tumors, trastuzumab has dramatically improved therapeutic results when added to standard adjuvant treatment" 08/01/2005 - "Nevertheless, while trastuzumab is highly effective in many Her-2/neu overexpressing tumors, some do not respond" 02/26/2004 - "Moreover, COX-2 enzymatic inhibition dramatically reduced HER-2 protein levels, efficiently increased the cancer cells sensitility to chemotherapeutic treatment and acted in synergy with HER-2 inhibitor, trastuzumab" 08/01/1999 - "In vitro studies demonstrate that trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets" 08/01/2004 - "The in vivo analysis revealed a marked decrease in tumor size with the Ad-mda7 + Herceptin combination (P < .05)" Get all the results and reference details, order at left...
3.	Neoplasm Metastasis (Metastasis) 04/01/2006 - "Trastuzumab is highly effective for the treatment of liver and lung metastasis in HER2 overexpressing patients, while it is apparently ineffective for treating or preventing BM" 09/01/2006 - "Authors have speculated that this is due to improved systemic control of disease; however, a possibility is that trastuzumab may have a beneficial effect on cerebral metastases themselves" 02/01/2006 - "These reports showed that even after short term follow up one year of Herceptin resulted in improved disease free, metastases free and overall survival" 01/01/2006 - "Moreover, among patients who received trastuzumab as first line treatment, isolated brain metastases were the initial site of progression in 17% patients" 04/01/2008 - "Several studies had analyzed if metastases in the brain during treatment with trastuzumab have increased in comparison with the pretrastuzumab era" Get all the results and reference details, order at left...
4.	Carcinoma (Carcinomatosis) 01/01/2001 - "Thus, our study suggests that anti-HER2/neu therapy with Herceptin is beneficial for patients with aggressive salivary duct carcinoma." 09/01/2002 - "Further research is warranted on the possible association of HER2 expression with chemosensitivitiy in urothelial carcinoma as well as the efficacy of HER2-targeted therapies (such as trastuzumab) for patients with high-grade, muscle-invasive urothelial carcinoma of the bladder." 10/01/2007 - "Immunohistochemistry or FISH for HER2/neu have been widely performed in numerous institutions and provide the gold standard for the treatment of trastuzumab in patients with breast carcinoma" 03/01/2005 - "Additionally, repeated stereotactic radiosurgery as gammaknife combination therapy synchronously with systematic trastuzumab-based therapy was useful for the treatment of metastatic breast carcinoma." 02/01/2000 - "Evaluation of the efficacy of trastuzumab in Her-2 overexpressors with carcinoma of unknown primary site is indicated." Get all the results and reference details, order at left...
5.	Disease Progression 10/01/2004 - "The benefits noted with trastuzumab-containing regimens were documented in clinical trials where trastuzumab was given until disease progression" 09/01/2004 - "MATERIALS AND METHODS: Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented" 04/01/2004 - "We conducted a retrospective case review study of women with HER2-positive MBC who continued to receive trastuzumab beyond disease progression" 03/15/2004 - "PATIENTS AND METHODS: A total of 247 patients with documented disease progression received weekly intravenous trastuzumab in the extension study" 03/15/2004 - "We conducted an extension study to this trial to obtain additional safety information and to provide trastuzumab following disease progression" Get all the results and reference details, order at left...
134 Diseases and 1618 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	trastuzumab (Herceptin)
2.	Paclitaxel (Taxol)
3.	docetaxel (Taxotere)
4.	Epidermal Growth Factor Receptor (EGF Receptor)
5.	vinorelbine (Navelbine)
6.	gemcitabine
7.	taxane
8.	capecitabine (Xeloda)
9.	gefitinib (Iressa)
10.	Protein-Tyrosine Kinases (Tyrosine Kinase)
303 Drugs and Important Bio-Agents and 966 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Adjuvant Chemotherapy
3.	Aftercare (After-Treatment)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Neoadjuvant Therapy
26 Therapies and Procedures and 378 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>